Intralymphatic immunotherapy (ILIT) is a quick and easy immunotherapy technique that has the potential to be extremely successful. There have been a variety of outcomes, and research is still being done to determine the treatment’s true worth. The methods used to evaluate the effects of clinical trials were so diverse that it was challenging to compare research to one another.

There have been some improvements; the significance of injecting into the lymph node has been highlighted, and therapy with a variety of medications has shown to be effective. The medication has been demonstrated in meta-analyses to be safe and effective as a short-term desensitizing agent, with no known major adverse effects. It had to be demonstrated that ILIT also has long-term tolerance-increasing effects. There may be a long-term effect, according to preliminary research.

The immune system’s defenses are strengthened when an allergen is injected directly into a lymph node. ILIT is risk-free, causes desensitization, and very certainly also causes tolerance. Compared to other treatment methods, compliance increased. If ILIT lives up to its potential, it will be a desirable treatment choice for allergy patients.

Reference: journals.lww.com/co-allergy/Abstract/2022/12000/Strengthening_the_case_for_intralymphatic.8.aspx